Affinage

FGD5

FYVE, RhoGEF and PH domain-containing protein 5 · UniProt Q6ZNL6

Length
1462 aa
Mass
159.9 kDa
Annotated
2026-06-09
90 papers in source corpus 11 papers cited in narrative 11 extracted findings
Cross-family judge vs UniProt: tie faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

FGD5 is an endothelial-enriched Rho-family guanine nucleotide exchange factor that couples vascular growth-factor receptor signaling to actin remodeling, junction stability, and vascular pruning (PMID:22328776, PMID:22661514). Purified FGD5 acts through a DH (Dbl-homology) domain to load GTP onto Rho-family GTPases; in vitro reconstitution shows it preferentially activates Rac1, while in endothelial cells it also drives Cdc42 activation downstream of VEGF (PMID:31601145, PMID:22328776). A central function is the stabilization of VEGFR2: FGD5 localizes to EEA1-positive recycling endosomes where it forms a complex with VEGFR2, protecting the receptor from proteasomal and lysosomal degradation and sustaining endosomal VEGFR2 coupling to PI3K/mTORC2/Akt-dependent cortactin activation and directional migration (PMID:28927665, PMID:29051140). Its RhoGEF-generated Rac1-GTP is likewise required for endothelial CXCR4/CXCL12-driven PI3K-β and Akt signaling (PMID:34882832). FGD5 is integrated into junctional control as a two-step process—membrane recruitment followed by Y820 tyrosine phosphorylation downstream of Tie-2/VE-PTP—that activates Cdc42 to stabilize endothelial cell contacts (PMID:31267715), and it conversely promotes apoptosis-induced vascular pruning via the hey1-p53 pathway (PMID:22661514). Beyond the vasculature, genetic reporter and conditional alleles establish FGD5 as a near-exclusive marker of bone-marrow HSCs, including an IFN-γ-resistant quiescent subpopulation (PMID:24958848, PMID:35768035), and in mammary basal cells FGD5 suppresses ATF3 to induce CXCL14 secretion, engaging a CXCR4/ERK-hedgehog endothelial feedback loop that supports ductal morphogenesis (PMID:38821057).

Mechanistic history

Synthesis pass · year-by-year structured walk · 6 steps
  1. 2012 High

    Established FGD5 as an endothelial Cdc42 activator whose function determines whether vessels grow or are pruned, defining its first vascular role.

    Evidence Loss/gain-of-function in vitro and in vivo angiogenesis assays plus direct Cdc42 binding and hey1-p53 pathway identification in endothelial cells

    PMID:22328776 PMID:22661514

    Open questions at the time
    • Did not resolve whether FGD5 GEF specificity is restricted to Cdc42
    • Mechanism linking GEF activity to hey1-p53 induction not detailed
  2. 2014 High

    Defined FGD5 expression as a near-exclusive HSC marker and built genetic tools (reporter, CreERT2) for HSC tracing, separating its dispensable role in hematopoiesis from a requirement in embryonic development.

    Evidence Targeted reporter knock-in/knock-out alleles, bone marrow transplantation, and tamoxifen-inducible conditional deletion in mice

    PMID:24958848

    Open questions at the time
    • Molecular function of FGD5 within HSCs not addressed
    • Cause of embryonic requirement not mechanistically defined
  3. 2017 High

    Showed FGD5 stabilizes VEGFR2 on endosomes by blocking proteasomal/lysosomal degradation and sustaining PI3K/mTORC2/Akt-cortactin signaling, identifying a receptor-trafficking function distinct from its GEF role.

    Evidence Endosomal colocalization (EEA1/VEGFR2), proteasome inhibitor rescue, co-immunoprecipitation, and 3D sprouting/chemotaxis assays in endothelial cells

    PMID:28927665 PMID:29051140

    Open questions at the time
    • Whether FGD5-VEGFR2 binding is direct or bridged not established
    • Relationship between trafficking function and GEF catalysis unresolved
  4. 2019 High

    Reconstituted FGD5 catalysis with purified protein showing preferential Rac1 (not Cdc42) activation, and identified Y820 phosphorylation downstream of Tie-2/VE-PTP as a junction-stabilizing activation step.

    Evidence In vitro GEF enzyme assay, pull-down/co-IP, selective inhibitor screen, and Y820 mutagenesis with permeability and Cdc42 activity assays

    PMID:31267715 PMID:31601145

    Open questions at the time
    • In vitro Rac1 preference versus cellular Cdc42 activation not fully reconciled
    • Kinase directly phosphorylating Y820 not identified
    • Recruitment signal preceding Y820 phosphorylation undefined
  5. 2021 Medium

    Extended the receptor-stabilization mechanism beyond the vasculature, showing FGD5 binds EGFR and reduces its ubiquitination to sustain STAT3 signaling in gastric cancer.

    Evidence Co-immunoprecipitation, ubiquitination assay, shRNA knockdown, and xenograft tumorigenesis with STAT3 readout

    PMID:34034092

    Open questions at the time
    • Single-lab co-IP without reciprocal validation in independent systems
    • Whether GEF activity contributes to EGFR stabilization untested
  6. 2022 High

    Tied FGD5's RhoGEF/Rac1 catalytic activity directly to CXCR4-dependent PI3K-β signaling and defined a basal-cell ATF3-CXCL14-CXCR4/ERK-hedgehog axis driving mammary ductal morphogenesis, plus marked an IFN-γ-resistant HSC subset.

    Evidence RhoGEF-deficient mutant rescue and Rac1 inhibition epistasis; conditional KO/KI mouse models with pathway dissection; Fgd5 reporter mice with IFN-γ stimulation

    PMID:34882832 PMID:35768035 PMID:38821057

    Open questions at the time
    • How FGD5 suppresses ATF3 transcriptional activity mechanistically unknown
    • Molecular basis of IFN-γ resistance in Fgd5+ HSCs uncharacterized

Open questions

Synthesis pass · forward-looking unresolved questions
  • Whether FGD5's GTPase specificity (Rac1 vs Cdc42) is context-switched and how its receptor-stabilization and GEF functions are mechanistically integrated remain open.
  • No structural model of FGD5 engaging both receptor cargo and GTPase substrate
  • Determinants selecting Rac1 versus Cdc42 in vivo undefined
  • FGD5's intrinsic function within HSCs still unresolved

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0098772 molecular function regulator activity 3
Localization
GO:0005768 endosome 2 GO:0005886 plasma membrane 2
Pathway
R-HSA-162582 Signal Transduction 3 R-HSA-1266738 Developmental Biology 2
Partners
CDC42CXCR4EGFRRAC1VEGFR2

Evidence

Reading pass · 11 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2012 FGD5 directly binds and activates Cdc42 in endothelial cells, promoting apoptosis-induced vaso-obliteration via induction of the hey1-p53 pathway, thereby acting as a genetic regulator of vascular pruning. Loss- and gain-of-function studies (in vitro tube-formation, aortic-ring, coated-bead assays; in vivo coated-bead plug assays and murine retina model); direct binding assay for Cdc42 activation Circulation High 22661514
2012 FGD5 is selectively expressed in human vascular endothelial cells, localizes to peripheral membrane ruffles and perinuclear regions, activates Cdc42, and mediates VEGF-induced activation of Cdc42 and ERK. Knockdown attenuates VEGF-promoted capillary-like network formation, permeability, directional movement, proliferation, and Golgi reorientation. Immunofluorescence microscopy (subcellular localization); siRNA knockdown with functional assays (network formation, permeability, directional movement, proliferation assays); overexpression Cdc42 activity assay Arteriosclerosis, thrombosis, and vascular biology High 22328776
2014 Fgd5 is required for embryonic development but is not required for definitive hematopoiesis or HSC function. Reporter knock-in mice demonstrate that Fgd5 expression near-exclusively labels HSCs in the bone marrow, and an Fgd5-CreERT2 allele allows tamoxifen-inducible HSC-specific deletion. Targeted reporter knock-in/knock-out alleles in mice; bone marrow transplantation (HSC activity assay); Fgd5-CreERT2 tamoxifen-inducible conditional deletion The Journal of experimental medicine High 24958848
2017 FGD5 localizes to the inner surface of the cell membrane and the outer surface of EEA1-positive endosomes carrying VEGFR2. FGD5 depletion accelerates VEGFR2 degradation via the proteasome (rescued by lactacystin), inhibiting endothelial cell migration toward VEGFA gradients, thus sustaining VEGFA signaling by inhibiting proteasome-mediated VEGFR2 degradation. Immunofluorescence colocalization (FGD5 and EEA1/VEGFR2 on endosomes); siRNA knockdown; VEGFR2 degradation assay with proteasomal inhibitor lactacystin; chemotaxis migration assay Cellular signalling High 28927665
2017 FGD5 forms a complex with VEGFR2 (co-immunoprecipitation) in resting and VEGF-stimulated endothelial cells, is enriched at the leading edge and endosomes, and loss of FGD5 reduces endosomal VEGFR2 coupling to PI3 kinase and diverts VEGFR2 to lysosomal degradation. FGD5 loss reduces mTORC2/Akt-dependent cortactin activation but does not alter VEGFR2 plasma membrane expression, Y1175 phosphorylation, or endocytosis. Co-immunoprecipitation; immunofluorescence; 3D sprouting angiogenesis assay; siRNA knockdown; Western blot for PI3K/mTORC2/Akt/cortactin signaling Arteriosclerosis, thrombosis, and vascular biology High 29051140
2019 Purified FGD5 preferentially activates Rac1 (not Cdc42) as shown by GEF enzyme assay; Rac1 directly binds FGD5 in pull-down and co-immunoprecipitation assays. The FGD5 DH domain is structurally homologous to the Rac1 GEF TrioN. Aurintricarboxylic acid selectively inhibits FGD5 GEF activity and Rac1 interaction without affecting TrioN. In vitro GEF enzyme assay with purified Fgd5; GST pull-down; co-immunoprecipitation; surface plasmon resonance small-molecule screen; structural comparison of DH domain Small GTPases High 31601145
2019 VE-PTP inhibition and Tie-2 activation induce tyrosine phosphorylation of FGD5 at Y820 (directly dephosphorylated by VE-PTP) and stimulate FGD5 translocation to cell contacts. FGD5 phosphorylation at Y820 is required for junction stabilization and Cdc42 activation by VE-PTP inhibition, but not for recruitment to cell contacts. FGD5 activation is a two-step process: membrane recruitment followed by Y820 phosphorylation. Phosphorylation mapping (Y820 mutagenesis); immunofluorescence (FGD5 translocation); in vitro and in vivo endothelial permeability assays; siRNA knockdown; actin cytoskeleton analysis EMBO reports High 31267715
2021 FGD5 interacts with EGFR (co-immunoprecipitation) in gastric cancer cells, decreases EGFR ubiquitination, and sustains activation of EGFR downstream signaling (STAT3/pSTAT3). FGD5 knockdown inhibits tumorigenesis and migration in vivo and in vitro; FGD5 expression is associated with tumor stage. Co-immunoprecipitation; ubiquitination assay; shRNA knockdown; immunofluorescence; in vivo xenograft; Western blot for STAT3 signaling Biochemical and biophysical research communications Medium 34034092
2022 FGD5 is enriched in mammary basal cells (BCs) and inhibits the transcriptional activity of ATF3, leading to transcriptional activation and secretion of CXCL14. CXCL14 then activates CXCR4/ERK signaling in mammary stromal endothelial cells, enhancing HIF-1α-regulated hedgehog ligand expression, creating a positive feedback loop promoting BC function. Conditional Fgd5 deletion reduced BC engraftment and ductal morphogenesis; conditional knockin increased them. Conditional deletion and knockin mouse models; mechanistic assays (ATF3 transcriptional activity, CXCL14/CXCR4/ERK signaling); ductal morphogenesis quantification Developmental cell High 38821057
2022 FGD5 regulates endothelial CXCR4-dependent PI3 kinase-β signaling. FGD5 loss abolishes CXCL12-stimulated PI3K-β and Akt activation. A RhoGEF-deficient (Dbl domain-deleted) FGD5 mutant failed to rescue PI3K signaling, indicating that FGD5's RhoGEF activity (generating Rac1-GTP) is required for CXCR4-dependent PI3K-β activation. Inhibition of Rac1 recapitulated FGD5 deficiency signaling defects. siRNA knockdown; RhoGEF-deficient mutant overexpression; Rac1 inhibition; Akt/PI3K-β phosphorylation assays; sprouting angiogenesis ex vivo; PI3K-β mutant with inactivated Rho-binding domain FASEB journal High 34882832
2022 FGD5 marks a subset of HSCs that do not divide or differentiate in response to IFN-γ, suggesting FGD5 identifies an IFN-γ-resistant HSC subpopulation that may preserve the HSC compartment during emergency hematopoiesis. Fgd5 reporter mice; IFN-γ stimulation; division/differentiation assays on Fgd5+ vs Fgd5- HSC populations Experimental hematology Medium 35768035

Source papers

Stage 0 corpus · 90 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2022 Exosome-derived FGD5-AS1 promotes tumor-associated macrophage M2 polarization-mediated pancreatic cancer cell proliferation and metastasis. Cancer letters 173 35718269
2014 Fgd5 identifies hematopoietic stem cells in the murine bone marrow. The Journal of experimental medicine 161 24958848
2019 Long noncoding RNA FGD5-AS1 promotes colorectal cancer cell proliferation, migration, and invasion through upregulating CDCA7 via sponging miR-302e. In vitro cellular & developmental biology. Animal 64 31332696
2012 Endothelial cell-specific FGD5 involvement in vascular pruning defines neovessel fate in mice. Circulation 62 22661514
2012 FGD5 mediates proangiogenic action of vascular endothelial growth factor in human vascular endothelial cells. Arteriosclerosis, thrombosis, and vascular biology 57 22328776
2019 Abnormal expression of long noncoding RNA FGD5-AS1 affects the development of periodontitis through regulating miR-142-3p/SOCS6/NF-κB pathway. Artificial cells, nanomedicine, and biotechnology 54 31144533
2020 Long non-coding RNA FGD5-AS1 promotes non-small cell lung cancer cell proliferation through sponging hsa-miR-107 to up-regulate FGFRL1. Bioscience reports 53 31919528
2021 Thalidomide suppresses angiogenesis and immune evasion via lncRNA FGD5-AS1/miR-454-3p/ZEB1 axis-mediated VEGFA expression and PD-1/PD-L1 checkpoint in NSCLC. Chemico-biological interactions 44 34520751
2021 Targeting EGFR sensitizes 5-Fu-resistant colon cancer cells through modification of the lncRNA-FGD5-AS1-miR-330-3p-Hexokinase 2 axis. Molecular therapy oncolytics 40 34589581
2020 LncRNA FGD5-AS1 can be predicted as therapeutic target in oral cancer. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 39 31899825
2024 lncRNA FGD5-AS1 is required for gastric cancer proliferation by inhibiting cell senescence and ROS production via stabilizing YBX1. Journal of experimental & clinical cancer research : CR 35 38965605
2020 Elevation of FGD5-AS1 contributes to cell progression by improving cisplatin resistance against non-small cell lung cancer cells through regulating miR-140-5p/WEE1 axis. Gene 35 32534055
2020 Long Non-coding RNA FGD5-AS1 Regulates Cancer Cell Proliferation and Chemoresistance in Gastric Cancer Through miR-153-3p/CITED2 Axis. Frontiers in genetics 34 32849774
2020 FGD5‑AS1 promotes cisplatin resistance of human lung adenocarcinoma cell via the miR‑142‑5p/PD‑L1 axis. International journal of molecular medicine 31 33416094
2021 Long Noncoding RNA FGD5-AS1 Knockdown Decrease Viability, Migration, and Invasion of Non-Small Cell Lung Cancer (NSCLC) Cells by Regulating the MicroRNA-944/MACC1 Axis. Technology in cancer research & treatment 29 33550920
2021 LncRNA FGD5-AS1 Facilitates the Radioresistance of Breast Cancer Cells by Enhancing MACC1 Expression Through Competitively Sponging miR-497-5p. Frontiers in oncology 27 34221989
2021 Activation of FGD5-AS1 Promotes Progression of Cervical Cancer through Regulating BST2 to Inhibit Macrophage M1 Polarization. Journal of immunology research 27 34692852
2020 FGD5-AS1 facilitates glioblastoma progression by activation of Wnt/β-catenin signaling via regulating miR-129-5p/HNRNPK axis. Life sciences 27 32585241
2019 VE-PTP inhibition stabilizes endothelial junctions by activating FGD5. EMBO reports 27 31267715
2021 LncRNA FGD5-AS1 accelerates cell proliferation in pancreatic cancer by regulating miR-520a-3p/KIAA1522 axis. Cancer biology & therapy 26 33794727
2021 lncRNA FGD5‑AS1 promotes breast cancer progression by regulating the hsa‑miR‑195‑5p/NUAK2 axis. Molecular medicine reports 26 33880593
2020 LncRNA FGD5-AS1 promotes tumor growth by regulating MCL1 via sponging miR-153-3p in oral cancer. Aging 26 32675387
2021 The LncRNA FGD5-AS1/miR-497-5p axis regulates septin 2 (SEPT2) to accelerate cancer progression and increase cisplatin-resistance in laryngeal squamous cell carcinoma. Molecular carcinogenesis 25 34003510
2021 FGD5-AS1 Is a Hub lncRNA ceRNA in Hearts With Tetralogy of Fallot Which Regulates Congenital Heart Disease Genes Transcriptionally and Epigenetically. Frontiers in cell and developmental biology 23 34046402
2020 LncRNA FGD5-AS1/miR-5590-3p axis facilitates the proliferation and metastasis of renal cell carcinoma through ERK/AKT signalling. European review for medical and pharmacological sciences 23 32964964
2022 The role of long non-coding RNA FGD5-AS1 in cancer. Bioengineered 22 35475392
2020 lncRNA FGD5 antisense RNA 1 upregulates RORA to suppress hypoxic injury of human cardiomyocyte cells by inhibiting oxidative stress and apoptosis via miR‑195. Molecular medicine reports 22 33174051
2021 LncRNA FGD5-AS1 promotes the malignant phenotypes of ovarian cancer cells via targeting miR-142-5p. Apoptosis : an international journal on programmed cell death 21 33974163
2017 FGD5 sustains vascular endothelial growth factor A (VEGFA) signaling through inhibition of proteasome-mediated VEGF receptor 2 degradation. Cellular signalling 21 28927665
2022 Tumor-Derived Exosome FGD5-AS1 Promotes Angiogenesis, Vascular Permeability, and Metastasis in Thyroid Cancer by Targeting the miR-6838-5p/VAV2 Axis. Journal of oncology 19 35528244
2021 FGD5‑AS1 is an oncogenic lncRNA in pancreatic cancer and regulates the Wnt/β‑catenin signaling pathway via miR‑577. Oncology reports 19 34821374
2021 Long non-coding RNA FGD5-AS1 contributes to cisplatin resistance in hepatocellular carcinoma via sponging microRNA-153-3p by upregulating Twinfilin Actin Binding Protein 1 (TWF1). Bioengineered 17 34519634
2021 Silencing of Long Non-Coding RNA FGD5-AS1 Inhibits the Progression of Non-Small Cell Lung Cancer by Regulating the miR-493-5p/DDX5 Axis. Technology in cancer research & treatment 16 33550957
2021 FGD5-AS1 Inhibits Osteoarthritis Development by Modulating miR-302d-3p/TGFBR2 Axis. Cartilage 16 33834880
2020 Long Noncoding RNA FGD5-AS1 Acts as a Competing Endogenous RNA on microRNA-383 to Enhance the Malignant Characteristics of Esophageal Squamous Cell Carcinoma by Increasing SP1 Expression. Cancer management and research 16 32273764
2017 FGD5 Regulates VEGF Receptor-2 Coupling to PI3 Kinase and Receptor Recycling. Arteriosclerosis, thrombosis, and vascular biology 16 29051140
2022 LncRNA FGD5-AS1 potentiates autophagy-associated doxorubicin resistance by regulating the miR-154-5p/WNT5A axis in osteosarcoma. Cell biology international 15 36041209
2021 Long non-coding RNA FGD5-AS1 enhances osteosarcoma cell proliferation and migration by targeting miR-506-3p/RAB3D axis. Human cell 15 33891267
2022 EBF1-mediated up-regulation of lncRNA FGD5-AS1 facilitates osteosarcoma progression by regulating miR-124-3p/G3BP2 axis as a ceRNA. Journal of orthopaedic surgery and research 14 35761386
2021 Upregulation of Long Noncoding RNA FGD5-AS1 Ameliorates Myocardial Ischemia/Reperfusion Injury via MicroRNA-106a-5p and MicroRNA-106b-5p. Journal of cardiovascular pharmacology 14 34173804
2020 Study on Targeting Relationship Between miR-320b and FGD5-AS1 and Its Effect on Biological Function of Osteosarcoma Cells. Cancer management and research 14 33408528
2021 LncRNA FGD5-AS1 accelerates intracerebral hemorrhage injury in mice by adsorbing miR-6838-5p to target VEGFA. Brain research 13 34902342
2020 Long-Noncoding RNA FGD5-AS1 Enhances the Viability, Migration, and Invasion of Glioblastoma Cells by Regulating the miR-103a-3p/TPD52 Axis. Cancer management and research 13 32848452
2021 Long non‑coding RNA FGD5‑AS1/microRNA‑133a‑3p upregulates aquaporin 1 to decrease the inflammatory response in LPS‑induced sepsis. Molecular medicine reports 12 34498707
2019 Fgd5 is a Rac1-specific Rho GEF that is selectively inhibited by aurintricarboxylic acid. Small GTPases 12 31601145
2019 LncRNA FGD5-AS1 acts as a competing endogenous RNA for miRNA-223 to lessen oxygen-glucose deprivation and simulated reperfusion (OGD/R)-induced neurons injury. Folia neuropathologica 11 32337949
2023 Common Variants on FGD5 Increase Hazard of Mortality or Rehospitalization in Patients With Heart Failure From the ASCEND-HF Trial. Circulation. Heart failure 10 37725680
2022 LncRNA FGD5-AS1 enhances the proliferation and stemness of hepatocellular carcinoma cells through targeting miR-223 and regulating the expression of ECT2 and FAT1. Hepatology research : the official journal of the Japan Society of Hepatology 10 35366388
2021 LncRNA FGD5-AS1 functions as an oncogene to upregulate GTPBP4 expression by sponging miR-873-5p in hepatocellular carcinoma. European journal of histochemistry : EJH 10 34783233
2023 METTL3-induced FGD5-AS1 contributes to the tumorigenesis and PD-1/PD-L1 checkpoint to enhance the resistance to paclitaxel of endometrial carcinoma. Journal of cellular and molecular medicine 9 37755125
2021 Expression and crucial role of long non-coding RNA FGD5-AS1 in human cancers. American journal of translational research 9 34786036
2018 Characterization of FGD5 Expression in Primary Breast Cancers and Lymph Node Metastases. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 9 30052477
2023 BHLHE40, a potential immune therapy target, regulated by FGD5-AS1/miR-15a-5p in pancreatic cancer. Scientific reports 8 37773521
2023 Long noncoding RNA FGD5-AS1 alleviates childhood IgA nephropathy by targeting PTEN-mediated JNK/c-Jun signaling pathway via miR-196b-5p. Experimental cell research 7 36641136
2023 FGD5-AS1/miR-5590-3p/PINK1 induces Lenvatinib resistance in hepatocellular carcinoma. Cellular signalling 7 37517671
2022 lncRNA FGD5-AS1 Regulates Bone Marrow Stem Cell Proliferation and Apoptosis by Affecting miR-296-5p/STAT3 Axis in Steroid-Induced Osteonecrosis of the Femoral Head. Journal of healthcare engineering 7 35190765
2022 LncRNA FGD5-AS1 reduces cardiomyocyte apoptosis and inflammation by modulating Akt and miR-223-3p expression. American journal of translational research 7 36247255
2021 Long Non-Coding RNA FGD5-AS1 Induced by Chlamydia trachomatis Infection Inhibits Apoptosis via Wnt/β-Catenin Signaling Pathway. Frontiers in cellular and infection microbiology 7 34568091
2021 FGD5-AS1 facilitates the osteogenic differentiation of human bone marrow-derived mesenchymal stem cells via targeting the miR-506-3p/BMP7 axis. Journal of orthopaedic surgery and research 7 34772438
2020 Long Noncoding RNA FGD5-AS1 Promotes Glioma Cell Proliferation, Migration and Invasion by Regulating wnt/β-Catenin Pathway. Cancer management and research 7 32801867
2021 FGD5 facilitates tumor growth by regulating EGFR ubiquitination in gastric cancer. Biochemical and biophysical research communications 6 34034092
2024 Long non-coding RNA FGD5 antisense RNA 1 targets Baculovirus inhibitor 5 via microRNA-497-5p to alleviate calcific aortic valve disease. Clinical hemorheology and microcirculation 5 37355887
2024 FGD5 in basal cells induces CXCL14 secretion that initiates a feedback loop to promote murine mammary epithelial growth and differentiation. Developmental cell 5 38821057
2023 LncRNA FGD5-AS1 Promotes Abdominal Aortic Aneurysm Growth Through the Activation of MMP3 in Vascular Smooth Muscle Cells. International heart journal 5 37197924
2022 Lncrna FGD5-AS1 Aggravates Myocardial Ischemia-Reperfusion Injury by Sponging Mir-129-5p. Iranian journal of public health 5 36415802
2023 LncRNA FGD5-AS1 Alleviates Inflammation in Allergic Rhinitis through the miR-223-3p/COX11 Axis. International archives of allergy and immunology 4 38071964
2022 LncRNA FGD5-AS1 drives the malignant development of gastric cancer by negatively interacting with FZD3. Polish journal of pathology : official journal of the Polish Society of Pathologists 4 35848483
2021 Corrigendum: LncRNA FGD5-AS1 Facilitates the Radioresistance of Breast Cancer Cells by Enhancing MACC1 Expression Through Competitively Sponging miR-497-5p. Frontiers in oncology 4 34504804
2023 High CTCF expression mediated by FGD5-AS1/miR-19a-3p axis is associated with immunosuppression and pancreatic cancer progression. Heliyon 3 38144356
2022 FGD5 regulates endothelial cell PI3 kinase-β to promote neo-angiogenesis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 3 34882832
2022 FGD5 marks a subpopulation of hematopoietic stem and progenitor cells that resist interferon-γ-mediated differentiation. Experimental hematology 3 35768035
2024 LncRNA-FGD5-AS1 promotes 5-Fu resistance of cervical cancer cells through modulating the miR-130a-3p-YTHDF2 axis. Journal of chemotherapy (Florence, Italy) 2 39643592
2024 Mechanism of RBM15 in the malignant proliferation of colorectal cancer cells through regulating the stability of LncRNA FGD5-AS1 via m6A modification. Experimental cell research 2 39701357
2023 Abnormal expression of long non-coding RNA FGD5-AS1 affects the development of ovarian cancer through regulating miR-107/RBBP6 axis. The Chinese journal of physiology 2 37322627
2022 Targeting the lncRNA FGD5-AS1/miR-497-5p/PD-L1 Axis Inhibits Malignant Phenotypes in Colon Cancer (CC). BioMed research international 2 35845947
2022 lncRNA FGD5-AS1 acts as a ceRNA to regulate lipopolysaccharide-induced injury via the miR-223-3p-3p/GAS5 axis in cardiomyocytes. Human & experimental toxicology 2 36445031
2025 LncRNA FGD5-AS1 Facilitates Hepatocellular Carcinoma Cell Stemness by Enhancing PKD1 mRNA Stability Through Binding With MSI2. Molecular carcinogenesis 1 39803743
2025 Regulatory interplay between lncRNA-FGD5-AS1 and miR-17-5p in non-small cell lung cancer progression: Implications for novel therapeutic strategies. Technology and health care : official journal of the European Society for Engineering and Medicine 1 40151994
2025 Exosomal FGD5-AS1 promotes proliferation of lung cancer cells under hypoxia by inhibiting miR-1179 and activating P-cadherin. Human cell 1 40820190
2023 FXR1 promotes glioma progression by downregulating microRNA-124-3p through long noncoding RNA FGD5-AS1 upregulation. Acta neurologica Belgica 1 37074635
2020 [miR-93-5p promotes invasion and migration of triple negative breast cancer cells by targeting FGD5]. Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology 1 32967763
2026 A multi-algorithm machine learning framework identifies FGD5, LRRC36, C8B, and MYOC as novel diagnostic biomarkers in lung adenocarcinoma. Discover oncology 0 41604006
2025 [Retracted] lncRNA FGD5‑AS1 promotes breast cancer progression by regulating the hsa‑miR‑195‑5p/NUAK2 axis. Molecular medicine reports 0 39950317
2025 METTL16-Mediated Upregulation of FGD5-AS1 Promotes Progression of Osteosarcoma through Targeting of miR-195-5p/SLC7A2 Axis. Critical reviews in eukaryotic gene expression 0 40530965
2025 Long noncoding RNA FGD5-AS1-encoded micropeptides improve right heart functions of pulmonary arterial hypertension through restricting the synthesis of hyaluronic acid. International journal of biological macromolecules 0 40669641
2025 [SRF promotes the progression of lung adenocarcinoma by regulating lncRNA FGD5-AS1]. Zhonghua zhong liu za zhi [Chinese journal of oncology] 0 40967878
2025 RETRACTION: lncRNA FGD5-AS1 Regulates Bone Marrow Stem Cell Proliferation and Apoptosis by Affecting miR-296-5p/STAT3 Axis in Steroid-Induced Osteonecrosis of the Femoral Head. Journal of healthcare engineering 0 41244032
2025 FGD5-AS1 and Th1/Th2 imbalance in the progression of diabetic nephropathy: evidence from bioinformatic and experimental validation. Clinical and experimental medicine 0 41286380
2023 Long Noncoding RNA FGD5-AS1 Promotes Glioma Cell Proliferation, Migration and Invasion by Regulating Wnt/β-Catenin Pathway [Retraction]. Cancer management and research 0 37529010
2021 Long Noncoding RNA FGD5-AS1 Acts as a Competing Endogenous RNA on microRNA-383 to Enhance the Malignant Characteristics of Esophageal Squamous Cell Carcinoma by Increasing SP1 Expression [Retraction]. Cancer management and research 0 34611443

Missed literature

Know a paper Affinage missed for FGD5? Flag it for the maintainers and the community.

No submissions yet.